NCT01565733View on ClinicalTrials.gov

Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes

CompletedOBSERVATIONAL

Enrollment

2,223

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart 30

Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.

Trial Locations (1)

PL-02-274

Novo Nordisk Investigational Site, Warsaw